ArticleVeterinary sciences2022
Tylvalosin Tartrate Improves the Health Status of Swine Herds during Immunization with Porcine Reproductive and Respiratory Syndrome Virus-Inactivated Vaccine.
Article in Veterinary sciences, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
7 citing papers in PubMed, 5 citations in OpenAlex.
- Tylvalosin tartrate inhibits PRRSV replication by suppressing cellular pyroptosis through the TLR4/NF-κB signaling pathway.Journal of virology · 2026Article
- Development and validation of UPLC-MS/MS method for pharmacokinetics and tissue distribution of Tylvalosin and its bioactive metabolites in swine.Veterinary research communications · 2026Article
- Enhanced efficacy of tylvalosin tartrate enteric-coated granules againstFrontiers in microbiology · 2026Article
- Next-Generation Sequencing Reveals Field Strain Dynamics and PRRSV-2 Clearance in Gilts When Using Tylvalosin During MLV Vaccination.Vaccines · 2025Article
- Breaking the PRRSV-2 Life Cycle in Porcine Alveolar Macrophages: Tylvalosin's Multi-Stage Inhibition.Veterinary sciences · 2025Article
- Use of Subtherapeutic Tylvalosin AgainstTransboundary and emerging diseases · 2025Article
- Analysis of whole transcriptome reveals the immune response to porcine reproductive and respiratory syndrome virus infection and tylvalosin tartrate treatment in the porcine alveolar macrophages.Frontiers in immunology · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 4 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Porcine reproductive and respiratory syndrome (PRRS) is a devastating disease that affects pigs and is responsible for severe economic losses. The commercial PRRSV-inactivated vaccine (CH-1a strain) in China was recently selected to control PRRS in large populations of PRRS-positive sows and was found to effectively reduce the rate of stillbirth abortion based on clinical observations. However, stress from vaccine inoculation (e.g., fever, anorexia, abortions, and slow body weight gain) usually appears after immunization on many swine farms. In this study, we fed piglets a diet medicated with tylvalosin tartrate during PRRSV-inactivated vaccine immunization. We found that tylvalosin tartrate attenuated the increase in total white blood cells induced by immunization at day one post-immunization (DPI) and induced an increase in monocyte counts after seven DPI. There was also attenuation in the intensity of the inflammatory response induced by vaccination and elevation of serum IFN-γ concentrations at three and seven DPI after immunization. The administration of tylvalosin tartrate could also attenuate the reduction in the percentage of CD8
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.